spacer
home > ebr > winter 2019 > spot the difference
PUBLICATIONS
European Biopharmaceutical Review

Spot the Difference

What and where is Scandinavia? Locally, Scandinavia is defined as Norway, Sweden, and Denmark. If one includes Finland and Iceland, it becomes the Nordic region. All five countries have historical and cultural similarities due to their geographical location. However, Norway, Sweden, and Denmark have a strong history of unions and mutually intelligible languages, as well as close cultural ties.

These close ties enable these small countries to create synergies and operate within a bigger market. However, it has not always been plain sailing. Harmonisation within the region has not always been successful, with questions being raised about whether the differences between the countries have been fully considered. When doing business with other regions in the world, one should always be prepared for not only the social and cultural differences, but also the local laws and regulations. Problems tend to occur when they are assumed to all be the same.

Identifying Regional Differences

When combined, many other less formal differences add to the misconception of the Scandinavian region. Country stereotypes exist: Danish decision-making hierarchy, bacon production, love of bike riding, and rye bread. Sweden is known for its democracy, manufacturing the Volvo, its love of meatballs, and IKEA. Norway sits somewhere between the two on democratic rights and decision-making, but they are renowned for their cross-country skiing ability and Viking history. The Norwegians and Swedes are more obsessed with rules, whereas the Danes think these are more ‘open to interpretation’ (although hopefully not when it comes to pharmaceuticals).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Tórben Thers Nørgaard is General Manager at PharmaLex Nordics. He studied chemical engineering at Danmarks Tekniske Universitet, Denmark, and has more than 20 years’ experience in the medical techology and pharma industry, having worked for Ferroperm, Coloplast, Weltec, ALK Abelló, Jacobsen Pharma, MedTech Advice, and, most recently, PharmaLex. Tórben’s key strengths include leadership, change management, business strategy (building and executing), operational excellence, and cross-functional and cultural collaboration.
spacer
Tórben Thers Nørgaard
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Pharma Services Announces Bottling Line Expansion to Support Customer Needs

Philadelphia, USA – February 5, 2019 PCI Pharma Services (PCI), a full-service provider of specialist outsourced drug manufacturing, clinical trial services, and commercial packaging to the global biopharmaceutical industry, is pleased to announce the expansion of its bottling line capacity at its Commercial Packaging site in Rockford, IL. Construction of the additional packaging suites began in March 2018 to add considerable footprint for primary and secondary packaging operations equipped with high speed tablet filling, cartoning, as well as in-line serialization and aggregation in support of increased customer demand. The new expansion will grow the robust bottling operation in Rockford by producing an extra 100 million bottles per year.
More info >>

White Papers

Clinical Trial Labelling – More Than Just Labels

Faubel & Co. Nachfolger GmbH

Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >>

 
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement